These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 7685840)
21. [Clinical evaluation of a prostate-specific antigen as a serum marker of prostatic cancer]. Park YC; Kiwamoto H; Nishioka T; Tsujihashi H; Mitsubayashi S; Matsuura T; Akiyama T; Kurita T; Miyamoto T Hinyokika Kiyo; 1987 Jun; 33(6):883-8. PubMed ID: 2445188 [TBL] [Abstract][Full Text] [Related]
22. Multiple marker evaluation in prostatic cancer using prostatic specific antigen, gamma-seminoprotein and prostatic acid phosphatase. Arai Y; Yoshiki T; Okada K; Yoshida O Urol Int; 1989; 44(3):135-40. PubMed ID: 2473564 [TBL] [Abstract][Full Text] [Related]
23. [Clinical evaluation of serum basic fetoprotein for prostatic cancer--comparative study with PAP, gamma-Sm and PSA]. Gotoh A; Mizuno Y; Takenaka A; Gohji K; Ogawa T; Arakawa S; Kamidono S; Harada K; Nagata H; Hirooka K Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):467-72. PubMed ID: 1712873 [TBL] [Abstract][Full Text] [Related]
24. Measurements of serum gamma-seminoprotein and prostate specific antigen evaluated for monitoring carcinoma of the prostate. Siddall JK; Shetty SD; Cooper EH Clin Chem; 1986 Nov; 32(11):2040-3. PubMed ID: 2430732 [TBL] [Abstract][Full Text] [Related]
25. [Usefulness of prostate specific antigen/gamma-seminoprotein ratio for diagnosis of prostate cancer]. Demura T; Watarai Y; Togashi M; Oohashi N; Chikaraishi T; Hirano T Nihon Hinyokika Gakkai Zasshi; 1993 Jun; 84(6):1046-53. PubMed ID: 7688442 [TBL] [Abstract][Full Text] [Related]
26. [Clinical and pathological study of tumor marker in benign prostatic hypertrophy and incidental prostatic cancer]. Sakai N; Ogawa T; Ishibashi Y; Fukuoka H; Sakanishi S Hinyokika Kiyo; 1991 Jun; 37(6):589-94. PubMed ID: 1716409 [TBL] [Abstract][Full Text] [Related]
27. [Tumor markers in prostate cancer]. Kuriyama M Gan To Kagaku Ryoho; 1994 Sep; 21(12):1915-22. PubMed ID: 7521999 [TBL] [Abstract][Full Text] [Related]
28. Serum gamma-seminoprotein determination in prostatic cancer. Shimazaki J; Akimoto S; Akakura K; Yoshiki T; Yoshida O; Okada K; Matsuoka K; Noda S; Eto K Hinyokika Kiyo; 1991 Apr; 37(4):341-7. PubMed ID: 1716404 [TBL] [Abstract][Full Text] [Related]
29. [Clinical study on PAP, gamma-Sm and PA as tumor markers in prostatic cancer patients]. Ohashi T; Akagi T; Irie S; Obama T; Nasu Y; Tohjoh S; Takeda K; Yoshimoto J; Matsumura Y; Ohmori H Nihon Hinyokika Gakkai Zasshi; 1987 Aug; 78(8):1403-8. PubMed ID: 2449560 [No Abstract] [Full Text] [Related]
31. [Prostate specific antigen (PSA)/gamma-seminoprotein ratio in the cases with PSA levels less than or equal to 10.0 ng/ml]. Demura T; Ohyama I; Togashi M; Ohashi N; Chikaraishi T; Hirano T; Koyanagi T Nihon Hinyokika Gakkai Zasshi; 1995 Feb; 86(2):296-303. PubMed ID: 7534845 [TBL] [Abstract][Full Text] [Related]
32. [Changes in tumor markers following cryosurgery of prostate carcinoma]. Higaki Y; Imamura K Hinyokika Kiyo; 1989 Feb; 35(2):265-70. PubMed ID: 2472049 [TBL] [Abstract][Full Text] [Related]
33. [Clinical study of tumor markers in prostatic carcinoma--an investigation on the simultaneous measurement of prostatic acid phosphatase (PAP), prostatic antigen (PA) and gamma-seminoprotein (gamma-Sm)]. Tsukamoto T; Kumamoto Y; Yamazaki K; Umehara T; Miyao N; Ohmura K; Iwazawa M Hinyokika Kiyo; 1988 Jun; 34(6):987-95. PubMed ID: 2464917 [TBL] [Abstract][Full Text] [Related]
34. Acid phosphatase, alkaline phosphatase and prostate-specific antigen--usefulness in the diagnosis of metastatic disease and follow-up. Bauer HW Prog Clin Biol Res; 1988; 269():33-42. PubMed ID: 2455908 [TBL] [Abstract][Full Text] [Related]
35. [Significance of prostatic acid phosphatase, gamma-seminoprotein and prostatic specific antigen in the urine. First report: the measurement of PAP, gamma-Sm and PA in the urine of patients with prostatic diseases]. Uchijima Y; Yoshida K; Saitoh H Hinyokika Kiyo; 1991 Oct; 37(10):1255-60. PubMed ID: 1721770 [TBL] [Abstract][Full Text] [Related]
36. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate. Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932 [TBL] [Abstract][Full Text] [Related]
37. [Role of gamma-seminoprotein (gamma-SM) and prostatic acid phosphatase (PAP) as tumor markers of prostatic cancer]. Watanabe M; Kitamura Y; Komatsubara S; Sakata Y Hinyokika Kiyo; 1988 Dec; 34(12):2135-41. PubMed ID: 2467542 [TBL] [Abstract][Full Text] [Related]
38. Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate. Dupont A; Cusan L; Gomez JL; Thibeault MM; Tremblay M; Labrie F J Urol; 1991 Oct; 146(4):1064-7; discussion 1067-8. PubMed ID: 1716697 [TBL] [Abstract][Full Text] [Related]
39. Diurnal rhythm of serum gamma-seminoprotein in patients with untreated prostate cancer: comparison of the original and revised assay kits. Akimoto S; Akakura K; Ohki T; Shimazaki J Int J Urol; 1994 Sep; 1(3):263-7. PubMed ID: 7542157 [TBL] [Abstract][Full Text] [Related]
40. Two prostate-specific antigens, gamma-seminoprotein and beta-microseminoprotein. Hara M; Kimura H J Lab Clin Med; 1989 May; 113(5):541-8. PubMed ID: 2654306 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]